CX157 (TriRima)

DRUG2 trials

Sponsors

CeNeRx BioPharma Inc.

Conditions

Major Depressive DisorderTreatment Resistant Depression

Phase 2

A Study of CX157 (TriRima) for the Treatment of Depression

CompletedNCT00739908

CeNeRx BioPharma Inc.Major Depressive Disorder

Start: 2008-09-30End: 2009-07-31Updated: 2012-06-27

Efficacy, Safety and Tolerability of CX157 in Treatment Resistant Depression

CompletedNCT01246908

CeNeRx BioPharma Inc.Treatment Resistant Depression

Start: 2010-11-30End: 2012-05-31Updated: 2012-07-10

Related Papers

Early symptomatic improvement affects treatment outcome in a study of major depressive disorder.

2017-09-086 citations

Use of band-pass filter analysis to evaluate outcomes in an antidepressant trial for treatment resistant patients.

2014-06-174 citations